Market News

Is This the Perfect Biotech Stock for Your Recession Portfolio?

Biotech stocks are generally extremely volatile, and the ARK Genomic Revolution ETF (ARKG) proves it. The biotech-heavy fund has declined more than 50% year-to-date, compared to the S&P 500 (SPX), which has dropped 20% year-to-date. However, not all biotech stocks are highly volatile. In this video, we look at a particular biotech stock that could add stability to your portfolio in a recession. The company has many FDA-approved products and numerous product candidates in the pipeline. It has a huge cash reserve, putting it in a position to continue to fund the development of its products.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More